Antiplatelet Market By Drug Class (Adenosine diphosphate (ADP) receptor inhibitors, Irreversible inhibitors cyclooxygenase, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2023-2032
The global antiplatelet market was valued at $3.8 billion in 2022, and is projected to reach $5.8 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032.
Antiplatelet agents, also known as antiplatelet drugs, are a class of medications that work to prevent the formation of blood clots by inhibiting the activation and aggregation of platelets, which are small blood cells responsible for clot formation. These medications are commonly used in the prevention and management of cardiovascular diseases, such as heart attacks and strokes.
Platelets play a crucial role in hemostasis, the process that stops bleeding after an injury. When a blood vessel is damaged, platelets adhere to the site and aggregate together, forming a clot that helps seal the injury. However, in certain medical conditions, such as atherosclerosis or irregular heart rhythms, blood clots can form within blood vessels inappropriately, leading to blockages that may result in heart attacks or strokes. Antiplatelet drugs work by interfering with different steps in the platelet activation and aggregation process. Some commonly used antiplatelet medications include aspirin, clopidogrel, ticagrelor, and prasugrel. These drugs inhibit platelet activation by blocking specific receptors or enzymes involved in the clotting pathway.
The antiplatelets market is driven by factors such as the increase in prevalence of cardiovascular diseases, such as heart attacks and stroke that drives the demand for antiplatelet drugs as a preventive and treatment measure thereby propelling the market growth. For instance, according to the American Association, the prevalence of stroke in 2020 was 89.1 million people across the globe. In addition, the ischemic stroke was 68.2 million, that of intracerebral hemorrhage was 18.9 million, and that of subarachnoid hemorrhage was 8.1 million across the globe. Thus, rise in the cases of cardiovascular diseases drives the demand for antiplatelet drugs and propels the market growth.
In addition, ongoing R&D efforts in the field of antiplatelet drugs lead to the discovery of novel agents with enhanced efficacy and safety profiles. The introduction of new and improved drugs stimulates market growth and attracts investment in the sector. For instance, Lee's Pharmaceutical Limited is conducting a phase 1 clinical trial to investigate the tolerability, safety, and pharmacokinetics of Anfibatate.
Furthermore, percutaneous coronary intervention (PCI), commonly known as angioplasty, is a surgical procedure used to treat coronary artery disease. Antiplatelet medications play a crucial role in PCI procedures, both during and after the intervention. Thus, the surge in usage of antiplatelet drugs in percutaneous coronary intervention contributes to the expansion of the antiplatelet market.
The antiplatelet market is segmented into drug class, route of administration, distribution channel, and region. As per drug class, the market is segregated into adenosine diphosphate (ADP) receptor inhibitors, irreversible inhibitors cyclooxygenase, and others. By route of administration, it is categorized into oral and injectable. Depending on distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the antiplatelet market are AstraZeneca plc, Bayer AG, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Cipla Ltd., Otsuka Pharmaceutical Co., Ltd., Lupin, Sanofi S.A., Daiichi Sankyo Company Limited, and Chiesi Farmaceutici S.p.A. Key players operating in the market have adopted product approval as their key strategies to expand their product portfolio.
Key Benefits For StakeholdersThis report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antiplatelet market analysis from 2022 to 2032 to identify the prevailing antiplatelet market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the antiplatelet market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global antiplatelet market trends, key players, market segments, application areas, and market growth strategies.
Key Market SegmentsBy Drug ClassAdenosine diphosphate (ADP) receptor inhibitors
Irreversible inhibitors cyclooxygenase
Others
By Route of AdministrationOral
Injectable
By Distribution ChannelHospital pharmacies
Drug store and retail pharmacies
Online providers
By RegionNorth America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Sanofi S.A.
Glenmark Pharmaceuticals Limited
Cipla Ltd.
Lupin
Bayer AG
Otsuka Pharmaceutical Co., Ltd.
Daiichi Sankyo Company Limited
Chiesi Farmaceutici S.p.A.
AstraZeneca plc
Eli Lilly and Company.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.